{"id":"tositumomab-and-iodine-i-131-tositumomab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Myelosuppression"},{"rate":"10-20%","effect":"Thyroid dysfunction"},{"rate":"5-10%","effect":"Hypersensitivity reactions"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201604","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tositumomab works by binding to the CD20 antigen on the surface of B cells, marking them for destruction by the immune system. This results in the depletion of B cells, which can be beneficial in treating certain types of cancer. The radioactive iodine (I-131) attached to tositumomab allows for targeted radiation therapy, further enhancing its therapeutic effects.","oneSentence":"Tositumomab is a monoclonal antibody that targets the CD20 antigen on B cells, leading to their destruction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:28.625Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma"}]},"trialDetails":[{"nctId":"NCT00006721","phase":"PHASE3","title":"S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-03","conditions":"Lymphoma","enrollment":571},{"nctId":"NCT00135200","phase":"PHASE2","title":"Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2005-08","conditions":"Multiple Myeloma","enrollment":16},{"nctId":"NCT00006695","phase":"PHASE2","title":"Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-04-01","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT01484093","phase":"PHASE1, PHASE2","title":"Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-11-29","conditions":"Mantle Cell Lymphoma","enrollment":96},{"nctId":"NCT00479167","phase":"PHASE2","title":"A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2007-05","conditions":"Follicular Lymphoma","enrollment":1},{"nctId":"NCT00329030","phase":"PHASE3","title":"Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-12","conditions":"Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Non-Hodgkin","enrollment":224},{"nctId":"NCT00992992","phase":"PHASE2","title":"Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-06-28","conditions":"Lymphoma, Mantle-Cell","enrollment":25},{"nctId":"NCT00770224","phase":"PHASE2","title":"S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-04","conditions":"Lymphoma","enrollment":87},{"nctId":"NCT00416312","phase":"","title":"Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-07","conditions":"Lymphoma","enrollment":9},{"nctId":"NCT00777114","phase":"PHASE1","title":"Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-04-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":31},{"nctId":"NCT00484874","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-06","conditions":"Hodgkin's Disease","enrollment":12},{"nctId":"NCT00004874","phase":"PHASE3","title":"Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"1998-11","conditions":"Lymphoma","enrollment":31},{"nctId":"NCT00476047","phase":"PHASE2","title":"Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2007-02","conditions":"Lymphoid Leukemia in Remission, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia","enrollment":16},{"nctId":"NCT01536561","phase":"PHASE1","title":"Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1990-04-24","conditions":"Lymphoma, Non-Hodgkin","enrollment":59},{"nctId":"NCT00073918","phase":"PHASE2","title":"Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1999-02","conditions":"Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","enrollment":111},{"nctId":"NCT00992758","phase":"PHASE1","title":"Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-05-28","conditions":"Lymphoma, Non-Hodgkin","enrollment":11},{"nctId":"NCT00315731","phase":"PHASE1","title":"A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-31","conditions":"Lymphoma, Follicular","enrollment":15},{"nctId":"NCT00577629","phase":"PHASE2","title":"Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma","status":"COMPLETED","sponsor":"Duke University","startDate":"2005-06-18","conditions":"Lymphoma, B-Cell","enrollment":39},{"nctId":"NCT00490009","phase":"PHASE2","title":"Phase 2 Study of Bexxar in Relapsed/Refractory DLCL","status":"COMPLETED","sponsor":"Susan Knox","startDate":"2004-09","conditions":"Lymphoma","enrollment":9},{"nctId":"NCT00490490","phase":"PHASE2","title":"Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":8},{"nctId":"NCT01389076","phase":"PHASE2","title":"Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2011-07","conditions":"Follicular Lymphoma","enrollment":22},{"nctId":"NCT00950755","phase":"PHASE2","title":"Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1998-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":41},{"nctId":"NCT01573000","phase":"PHASE2","title":"A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1998-09","conditions":"Lymphoma, Non-Hodgkin","enrollment":78},{"nctId":"NCT00933335","phase":"PHASE2","title":"Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1998-08","conditions":"Lymphoma, Non-Hodgkin","enrollment":38},{"nctId":"NCT01663714","phase":"PHASE2","title":"Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-02","conditions":"Lymphoma, Non-Hodgkin","enrollment":30},{"nctId":"NCT00996996","phase":"PHASE2","title":"Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1996-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":77},{"nctId":"NCT00268203","phase":"PHASE2","title":"Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1998-09","conditions":"Lymphoma, Non-Hodgkin","enrollment":765},{"nctId":"NCT01868035","phase":"PHASE2","title":"Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":15},{"nctId":"NCT00268983","phase":"PHASE3","title":"Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Lymphoma, Non-Hodgkin","enrollment":14},{"nctId":"NCT00938041","phase":"PHASE2","title":"Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1998-04","conditions":"Lymphoma, Non-Hodgkin","enrollment":32},{"nctId":"NCT00989664","phase":"PHASE2","title":"Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1996-11","conditions":"Lymphoma, Non-Hodgkin","enrollment":60},{"nctId":"NCT01224821","phase":"PHASE2","title":"Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1995-12","conditions":"Lymphoma, Non-Hodgkin","enrollment":47},{"nctId":"NCT00996593","phase":"PHASE2","title":"Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1998-07","conditions":"Lymphoma, Non-Hodgkin","enrollment":43},{"nctId":"NCT00434629","phase":"PHASE1","title":"Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-02","conditions":"B-cell Lymphoma, Non-Hodgkin's Lymphoma","enrollment":16},{"nctId":"NCT01988272","phase":"","title":"Imaging Based Dosimetry for Individualized Internal Emitter Therapy","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-06","conditions":"Non-Hodgkin's Lymphoma","enrollment":33},{"nctId":"NCT00107380","phase":"PHASE2","title":"S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2005-11","conditions":"Lymphoma","enrollment":86},{"nctId":"NCT00240578","phase":"","title":"Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11","conditions":"Lymphoma, Non-Hodgkin","enrollment":88},{"nctId":"NCT00240591","phase":"","title":"Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Lymphoma, Non-Hodgkin","enrollment":150},{"nctId":"NCT00098566","phase":"","title":"Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2002-12","conditions":"Lymphoma, Quality of Life","enrollment":36},{"nctId":"NCT00319332","phase":"PHASE3","title":"A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Large-Cell, Follicular, Lymphoma, Follicular","enrollment":""},{"nctId":"NCT00073931","phase":"PHASE2","title":"Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1999-10","conditions":"Lymphoma","enrollment":25},{"nctId":"NCT00110071","phase":"PHASE1","title":"Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2005-01","conditions":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma","enrollment":38},{"nctId":"NCT00003784","phase":"PHASE2","title":"S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1999-05","conditions":"Lymphoma","enrollment":102},{"nctId":"NCT00240565","phase":"PHASE2","title":"Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-04","conditions":"Lymphoma, Non-Hodgkin","enrollment":93},{"nctId":"NCT00475332","phase":"PHASE2","title":"Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar","status":"TERMINATED","sponsor":"University of Florida","startDate":"2007-09","conditions":"Non-Hodgkin's Lymphoma, Follicular Lymphoma","enrollment":2},{"nctId":"NCT00062894","phase":"PHASE1, PHASE2","title":"Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-04","conditions":"Non-Hodgkin's Lymphoma","enrollment":12},{"nctId":"NCT00078598","phase":"PHASE3","title":"A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Corixa Corporation","startDate":"2004-04","conditions":"Non-Hodgkin's Lymphoma","enrollment":506},{"nctId":"NCT00022945","phase":"PHASE2","title":"Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Corixa Corporation","startDate":"","conditions":"Mantle Cell Lymphoma","enrollment":""},{"nctId":"NCT00022958","phase":"NA","title":"Expanded Access Study of Iodine-131 Anti-B1 Antibody","status":"UNKNOWN","sponsor":"Corixa Corporation","startDate":"1998-09","conditions":"Non-Hodgkin's Lymphoma","enrollment":""},{"nctId":"NCT00022906","phase":"PHASE1","title":"Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement","status":"UNKNOWN","sponsor":"Corixa Corporation","startDate":"1999-05","conditions":"Non-Hodgkin's Lymphoma","enrollment":24},{"nctId":"NCT00022932","phase":"PHASE2","title":"Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP","status":"UNKNOWN","sponsor":"Corixa Corporation","startDate":"2000-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":""},{"nctId":"NCT00022893","phase":"NA","title":"Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Corixa Corporation","startDate":"","conditions":"Non-Hodgkin's Lymphoma","enrollment":""},{"nctId":"NCT00022880","phase":"PHASE1","title":"Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"Corixa Corporation","startDate":"1999-07","conditions":"Chronic Lymphocytic Leukemia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bexxar Therapeutic Regimen","anti-B1 Antibody","Iodine I 131 Tositumomab"],"phase":"phase_3","status":"active","brandName":"Tositumomab and Iodine I 131 Tositumomab","genericName":"Tositumomab and Iodine I 131 Tositumomab","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tositumomab is a monoclonal antibody that targets the CD20 antigen on B cells, leading to their destruction. Used for Relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}